Editas Medicine, Inc.

Biotechnology • Healthcare • Cambridge, MA, United States • EDIT (NMS)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

617 401 9000 11 Hurley Street, Cambridge, MA 02141, United States Wikipedia

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Why Editas Medicine Stock Was Skyrocketing This Week - The Motley Fool

The Motley Fool • Aug 15

Clear Street raises Editas Medicine stock price target to $4.60 on extended cash runway - Investing.com

Investing.com • Nov 10

Editas Medicine (EDIT) Price Target Increased by 22.78% to 4.95 - Nasdaq

Nasdaq • Dec 6

Editas Medicine: Three Strikes And It's Out, Or Third Time’s The Charm? - Seeking Alpha

Seeking Alpha • Oct 14

Editas Medicine Announces Second Quarter 2025 Results and Business Updates - Yahoo Finance

Yahoo Finance • Aug 12

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Editas Medicine, Inc. had layoffs?

No layoff events have been recorded for Editas Medicine, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Editas Medicine, Inc. have?

Editas Medicine, Inc. has approximately 246 employees.

What industry is Editas Medicine, Inc. in?

Editas Medicine, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Editas Medicine, Inc. a publicly traded company?

Yes, Editas Medicine, Inc. is publicly traded under the ticker symbol EDIT on the NMS. The company has a market capitalization of approximately $0.20 billion.

Where is Editas Medicine, Inc. headquartered?

Editas Medicine, Inc. is headquartered in Cambridge, MA, United States at 11 Hurley Street, Cambridge, MA 02141, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.